Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Rating) have received a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $63.75.
A number of equities analysts have issued reports on RCKT shares. Stifel Nicolaus increased their price objective on Rocket Pharmaceuticals from $63.00 to $67.00 in a report on Thursday, May 19th. William Blair restated an “outperform” rating on shares of Rocket Pharmaceuticals in a report on Thursday, May 5th. Needham & Company LLC reduced their price target on Rocket Pharmaceuticals from $75.00 to $62.00 and set a “buy” rating for the company in a report on Tuesday, May 17th. Raymond James assumed coverage on Rocket Pharmaceuticals in a report on Friday, July 8th. They set an “outperform” rating for the company. Finally, Chardan Capital lifted their price objective on Rocket Pharmaceuticals from $60.00 to $62.00 and gave the stock a “buy” rating in a report on Thursday, May 19th.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in RCKT. Ovata Capital Management Ltd purchased a new position in Rocket Pharmaceuticals in the 4th quarter worth approximately $82,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Rocket Pharmaceuticals by 41.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,645 shares of the biotechnology company’s stock worth $145,000 after acquiring an additional 1,946 shares during the last quarter. Amalgamated Bank bought a new stake in Rocket Pharmaceuticals in the 1st quarter worth approximately $106,000. Virtus ETF Advisers LLC increased its stake in Rocket Pharmaceuticals by 59.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 7,192 shares of the biotechnology company’s stock worth $157,000 after acquiring an additional 2,686 shares during the last quarter. Finally, Ensign Peak Advisors Inc bought a new stake in Rocket Pharmaceuticals in the 4th quarter worth approximately $169,000.
Rocket Pharmaceuticals Stock Performance
Shares of RCKT stock opened at $15.56 on Friday. The stock has a fifty day moving average of $14.00 and a 200 day moving average of $14.31. Rocket Pharmaceuticals has a 52 week low of $7.57 and a 52 week high of $37.44. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -5.76 and a beta of 1.68. The company has a quick ratio of 15.68, a current ratio of 15.68 and a debt-to-equity ratio of 0.05.
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Rating) last posted its quarterly earnings data on Thursday, May 5th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.03. During the same period in the prior year, the company posted ($0.65) earnings per share. As a group, research analysts expect that Rocket Pharmaceuticals will post -2.72 earnings per share for the current year.
About Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
Receive News & Ratings for Rocket Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.